Netchanok S, Wendy M, Marie C, Siobhan O
Twelve mice were randomly divided into 4 groups and injected into the tail vein with PBS, Ru(II)-OH, NP2, and NP4 (2 mg Ru/kg) on the days 1, 4, and 7
161, 485494.CrossRefGoogle ScholarPubMed Wali, JA, de Boo, HA, Derraik, JG, et al
No te la juegues con imitaciones
That comparison is from the studied FDA-approved products under trial conditions - it's relevant context for understanding why tirzepatide's higher efficacy average might justify its slightly higher price point, but it doesn't predict the gap in any individual patient's results
The table below summarizes evidence on these approaches based on current clinical data and real-world patterns